Cosentyx (also known by its generic name secukinumab) was approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults in January 2015 and approved for use in children 6 years and older in June 2021. Cosentyx is also approved to treat people with active psoriatic arthritis (PsA) ages 2 years and older.

For people with plaque psoriasis, Cosentyx is administered by injection under the skin at weeks 0, 1, 2, 3, and 4 and then every 4 weeks. Health care providers may recommend a different dosing schedule for patients with PsA. Cosentyx is also available as an intravenous (IV) infusion for adults with PsA.

To learn more, please visit the Cosentyx website.